Consensus CSPC Pharmaceutical Group Limited

Stocks

1093

HK1093012172

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2026-07-24 EDT			5-day change	1st Jan Change
8.550 ^HKD	+2.15%		+5.56%	+1.42%

07-24	CSPC Pharmaceutical Group Limited Announces Marketing Approval For Paliperidone Palmitate Injection	CI
07-22	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial of Sys6026 Injection for HPV Type 16 or 18 Related Cervical High Grade Squamous Intraepithelial Lesion in China	CI

Evolution of the Average Target: CSPC Pharmaceutical Group Limited

Evolution of the Target Price: CSPC Pharmaceutical Group Limited

Changes in Analyst Recommendations: CSPC Pharmaceutical Group Limited

d61c0718387e0c4ab.UIIad4jCY2PX-ldzCgOLVsThmxmFIDhqftvwlJfv4oM.ObYsJOCBMS6uzzYKcDDPGPKX2GzzR1IHLIy_-6HctOxm8y8RwfMNJrq8MA~e969f9ad866d9ff0f2f9e8bc1b169ac1

Analysts' recommendations: CSPC Pharmaceutical Group Limited

05-28	UOB Kay Hian Downgrades CSPC Pharmaceutical Group to Sell from Hold; Price Target is HK$6	MT
03-26	Jefferies Adjusts CSPC Pharmaceutical Group's Price Target to HK$7.20 From HK$5.90, Keeps at Underperform	MT
02-16	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy	MT
11-21	UOB Kay Hian Downgrades CSPC Pharmaceutical Group to Hold from Buy; Price Target is HK$8.50	MT
11-21	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$9.11 from HK$10.09, Keeps at Buy	MT
25-10-19	CSPC Pharmaceutical says JSKN003 granted breakthrough therapy designation in China	RE
25-10-13	CSPC Pharmaceutical announces NMPA acceptance of new drug application for Efmedaglutide Alfa Injection	RE
25-10-09	CSPC Pharmaceutical's Hypertriglyceridemia Drug Secures FDA Nod for US Trial	MT
25-08-25	Jefferies Adjusts CSPC Pharmaceutical Group's Price Target to HK$5.90 From HK$5, Keeps at Underperform	MT
25-07-17	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.09 From HK$10.22, Keeps at Buy	MT
25-07-16	Macquarie Upgrades CSPC Pharmaceutical Group to Outperform from Neutral; Price Target is HK$10.30	MT
25-06-16	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.22 From HK$8.02, Keeps at Buy	MT
25-05-29	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$8.02 From HK$6.55, Keeps at Buy	MT
25-03-31	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$6.55 From HK$6.48, Keeps at Buy	MT
25-02-26	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$6.48 From HK$7.02, Keeps at Buy	MT
24-11-18	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$7.02 From HK$8.46, Keeps at Buy	MT
24-10-22	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$8.46 From HK$9.29, Keeps at Buy	MT
24-08-23	Zhongtai International Downgrades CSPC Pharmaceutical to Neutral From Buy; Price Target is HK$6.10	MT
24-08-22	Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$9.29 From HK$9.83, Keeps at Buy	MT
24-08-22	Daiwa Securities Downgrades CSPC Pharmaceutical to Neutral From Outperform; Price Target is HK$6	MT
24-08-22	UOB Kay Hian Downgrades CSPC Pharmaceutical to Sell From Buy; Price Target is HK$5	MT
24-08-22	Bank of China International Downgrades CSPC Pharmaceutical to Hold From Buy; Price Target is HK$6.50	MT
24-07-23	Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$9.83 From HK$10.07, Keeps at Buy	MT
24-05-28	Nomura Adjusts CSPC Pharmaceutical’s Price Target to HK$10.07 From HK$9.41, Keeps at Buy	MT
24-03-14	Nomura Adjusts CSPC Pharmaceutical Group’s Price Target to HK$9.41 From HK$8.98, Keeps at Buy	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CSPC PHARMACEUTICAL GROUP LIMITED					+34.13%
	ELI LILLY AND COMPANY					+6.22%
	JOHNSON & JOHNSON					+2.73%
	ABBVIE INC.					+3.25%
	ROCHE HOLDING AG					+1.86%
	NOVARTIS AG					-1.09%
	ASTRAZENECA PLC					+25.51%
	NOVO NORDISK A/S					-1.06%
	AMGEN INC.					-5.15%
	GILEAD SCIENCES, INC.					+21.81%
	Average					+8.82%
	Weighted average by Cap.					+5.34%